Trial Profile
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Epirubicin; Ethiodized oil
- Indications Liver cancer
- Focus Therapeutic Use
- 31 May 2020 Status changed to completed, according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 30 Apr 2018 New trial record